Class II Transactivator Expression in Melanoma Cells Facilitates T-cell Engulfment

被引:0
作者
Lloyd, Mark C. [1 ,2 ]
Szekeres, Karoly [3 ]
Brown, Joel S. [2 ]
Blanck, George [3 ,4 ]
机构
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Analyt Microscopy Core, Tampa, FL 33612 USA
[2] Univ Illinois, Dept Biol Sci, Ecol & Evolut Div, Chicago, IL 60680 USA
[3] Univ S Florida, Morsani Coll Med, Dept Mol Med, Tampa, FL 33612 USA
[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Immunol Program, Tampa, FL 33612 USA
关键词
HLA class II; T-cell; CIITA; melanoma; immune response; Jurkat-C; MHC CLASS-II; GENE-EXPRESSION; MONOCLONAL-ANTIBODIES; SIGNALING PATHWAY; HLA; ACTIVATION; OCCUPANCY; INDUCTION; PROMOTER; HYBRIDS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Melanoma cells express high levels of HLA class II, cell surface antigen-presenting proteins, which is an anomalous phenotype among solid tumors. There has never been a satisfying explanation for how this HLA class II-positive phenotype is related to tumor development. Lugini and colleagues demonstrated that melanoma cells have the capacity to engulf T-cells. We considered the possibility that this capacity could be dependent on HLA class II expression. Materials and Methods: We co-cultured melanoma and CD4-positive, labeled, Jurkat-C T-cells. The melanoma cells were transformed with an expression vector for CIITA, the obligate HLA class II gene transactivator. We then assayed for the transfer of label to the melanoma cells. Results: CHTA expression facilitated engulfment of the T-cell material but not material from B-cells. Conclusion: The results suggest a possible mechanism for HLA class II-positive melanoma cells in blunting an anti-tumor response and suggest a possible target for melanoma therapy.
引用
收藏
页码:25 / 29
页数:5
相关论文
共 24 条
[1]   Upregulation of alpha and beta integrin subunits in metastatic macrophage-melanoma fusion hybrids [J].
Chakraborty, Ashok K. ;
Funasaka, Yoko ;
Ichihashi, Masamitsu ;
Pawelek, John M. .
MELANOMA RESEARCH, 2009, 19 (06) :343-349
[2]   Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors [J].
Cronin, Kevin ;
Escobar, Hernando ;
Szekeres, Karoly ;
Reyes-Vargas, Eduardo ;
Rockwood, Alan L. ;
Lloyd, Mark C. ;
Delgado, Julio C. ;
Blanck, George .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (04) :784-789
[3]   NONMETASTATIC TUMOR-CELLS ACQUIRE METASTATIC PROPERTIES FOLLOWING SOMATIC HYBRIDIZATION WITH NORMAL-CELLS [J].
DEBAETSELIER, P ;
ROOS, E ;
BRYS, L ;
REMELS, L ;
GOBERT, M ;
DEKEGEL, D ;
SEGAL, S ;
FELDMAN, M .
CANCER AND METASTASIS REVIEWS, 1984, 3 (01) :5-24
[4]   IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression [J].
Dunn, GP ;
Sheehan, KCF ;
Old, LJ ;
Schreiber, RD .
CANCER RESEARCH, 2005, 65 (08) :3447-3453
[5]   High level class II trans-activator induction does not occur with transient activation of the IFN-γ signaling pathway [J].
Eason, DD ;
Blanck, G .
JOURNAL OF IMMUNOLOGY, 2001, 166 (02) :1041-1048
[6]  
Goodwin BL, 2001, CELL GROWTH DIFFER, V12, P327
[7]   Cutting edge: The class II transactivator prevents activation-induced cell death by inhibiting Fas ligand gene expression [J].
Gourley, TS ;
Chang, CH .
JOURNAL OF IMMUNOLOGY, 2001, 166 (05) :2917-2921
[8]   Leukocyte-Cancer Cell Fusion: Initiator of the Warburg Effect in Malignancy? [J].
Lazova, Rossitza ;
Chakraborty, Ashok ;
Pawelek, John M. .
CELL FUSION IN HEALTH AND DISEASE II: CELL FUSION IN DISEASE, 2011, 714 :151-172
[9]  
Le E, 2005, ANTICANCER RES, V25, P3889
[10]  
LU YM, 1994, ONCOGENE, V9, P1015